Business Wire

ITEN to Launch the Industrial-Scale Production of Its All-Solid-State Battery Powency Product Family

Share

Electronica 2024 Trade Fair--ITEN, a pioneer in the development and production of solid-state batteries for electronics markets, today announced the production launch of its new Powency family of rechargeable Li-ion batteries. The new family consists of high-power density batteries, including for now the PWY0150S battery, available in pre-production, and the PWY0250S battery, available as engineering samples. Those first Powency batteries respectively have a capacity of 150µAh and 250µAh. The Powency product family, which is manufactured at the ITEN facility in France, is a testament to the demonstration of ITEN's technological and industrial leadership in the field of solid-state batteries.

ITEN will participate in the Electronica trade show in Munich from November 12 to 15, 2024 (Hall B4 - Stand E05) to showcase both PWY0150S and PWY0250S.

Powency PWY0150S and PWY0250S, solid-state energy storage in an unmatched form factor
The Powency PWS0150S and PWS0250S batteries are designed to deliver energy peaks to connected devices or to power electronic systems during a power outage. Both products feature a high-power density in an ultra-compact design, measuring 25mm³ and weighing 73 milligrams; they can supply the current levels required by connected devices operating with LAN wireless protocols. The Powency PWS0150S and PWS0250S are available as SMD devices, enabling an easy integration with automated production lines. Powency PWS0150S and PWS0250S are based on ITENS' all-solid-state battery technologies, contain no heavy metals, toxic chemicals or organic solvents, and can be recycled as passive electronic components.

Powency PWY0150S and PWY0250S, designed to address the energy efficiency challenges for the IoT and maintenance-free wireless sensors
Powering low-power, small-form-factor devices is a major obstacle in the emergence and broad implementation of the Internet of Things (IoT). The Powency products will enable IoT device makers to build high-performance Bluetooth Low Energy (BLE), 802.15.4, or NFC systems in an unrivaled form factor. They facilitate the widespread use of maintenance-free devices that harvest energy from external sources such as indoor or outdoor ambient light, ambient radio waves, and / or kinetic motion. PWY0150S is currently being manufactured in pre-series for numerous early-stage customers and serves as the ideal energy reservoir in autonomous sensors that are powered by Energy Harvesting.

Powency PWY0150S and PWY0250S, "Sustainability by design, process, and function"
The Powency product family, like all ITEN-developed products, is designed and manufactured to minimize its environmental impact and adhere to the company’s motto "sustainability by design, by process and by function." ITEN batteries are composed of ceramic, and are free of organic materials and critical metals like cobalt. They are rechargeable and completely recyclable.

Vincent Cobée, CEO of ITEN, said: "Our presence at the Electronica Trade Show, this essential event in the electronics industry, is very important for ITEN, at a key moment in the company’s growth. The commercial introduction and mass production of the Powency product family have indeed marked a significant milestone in the company's evolution. We were able to develop solutions that the market expected, in terms of both product and integration into our clients' various industrial processes, to provide a sustainable, high-performance, and genuinely integrated response. The trajectory will be further accelerated in the upcoming months by the introduction of a new battery that is even more potent, as well as the offering of two distinct solutions.”

More information available on www.iten.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241101283870/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye